Vitamin D Receptor Agonists: Opportunities and Challenges in Drug Discovery

Title: Vitamin D Receptor Agonists: Opportunities and Challenges in Drug Discovery

Volume: 6 Issue: 12

Author(s): Tadakatsu Takahashi and Kazumi Morikawa

Affiliation:

Keywords: Vitamin D, vitamin D receptor (VDR), nuclear receptor

Abstract: 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3) is an important hormone that regulates metabolism of calcium and phosphorus in small intestine, kidney, and bone, and its physiological action is expressed as ligand-dependent transcription activity mediated by vitamin D receptor (VDR). The VDR is found in various organs and cells including small intestine, kidney, and bone. In addition to the regulation of calcium metabolism, 1,25(OH)2D3 is involved in various biological reactions such as differentiation induction, antiproliferative effect, immunomodulatory effect, and regulation of cytokine and parathyroid hormone secretion. Thus, 1,25(OH)2D3 is expected to become a therapeutic drug for various related diseases. At present, a number of vitamin D derivatives are clinically applied to psoriasis, secondary hyperparathyroidism and osteoporosis but hypercalcemia and hypercalciuria are major concerns. Therefore, the current focus is directed toward new vitamin D derivatives with weak calcemic effects and a wide therapeutic window. In this summary, recent developments of new vitamin D derivatives for application in clinical treatment are described.

Cite this article as:

Takahashi Tadakatsu and Morikawa Kazumi, Vitamin D Receptor Agonists: Opportunities and Challenges in Drug Discovery, Current Topics in Medicinal Chemistry 2006; 6 (12) . https://dx.doi.org/10.2174/156802606777864917